Cargando…

SPR965, a Dual PI3K/mTOR Inhibitor, as a Targeted Therapy in Ovarian Cancer

SPR965 is an inhibitor of PI3K and mTOR C1/C2 and has demonstrated anti-tumorigenic activity in a variety of solid tumors. We sought to determine the effects of SPR965 on cell proliferation and tumor growth in human serous ovarian cancer cell lines and a transgenic mouse model of high grade serous o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tran, Arthur-Quan, Sullivan, Stephanie A., Chan, Leo Li-Ying, Yin, Yajie, Sun, Wenchuan, Fang, Ziwei, Dugar, Sundeep, Zhou, Chunxiao, Bae-Jump, Victoria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919852/ https://www.ncbi.nlm.nih.gov/pubmed/33659215 http://dx.doi.org/10.3389/fonc.2020.624498

Ejemplares similares

Asparagus officinalis Exhibits Anti-Tumorigenic and Anti-Metastatic Effects in Ovarian Cancer
por: Xu, Guangxu, et al.
Publicado: (2021)

Effect of a High-Fat Diet and Metformin on Placental mTOR Signaling in Mice
por: Grace, Matthew R., et al.
Publicado: (2019)

Oleic Acid Exhibits Anti-Proliferative and Anti-Invasive Activities via the PTEN/AKT/mTOR Pathway in Endometrial Cancer
por: Deng, Boer, et al.
Publicado: (2023)

Dual inhibition of glycolysis and glutaminolysis as a therapeutic strategy in the treatment of ovarian cancer
por: Sun, Li, et al.
Publicado: (2017)

Glutamine promotes ovarian cancer cell proliferation through the mTOR/S6 pathway
por: Yuan, Lingqin, et al.
Publicado: (2015)

Role of dual PI3/Akt and mTOR inhibition in Waldenstrom's Macroglobulinemia
por: Sacco, Antonio, et al.
Publicado: (2010)

Recent Advances in Dual PI3K/mTOR Inhibitors for Tumour Treatment
por: Wu, Xianbo, et al.
Publicado: (2022)

Dual mTOR/PI3K inhibition limits PI3K-dependent pathways activated upon mTOR inhibition in autosomal dominant polycystic kidney disease
por: Liu, Yang, et al.
Publicado: (2018)

Shrimp miR-965 transfers tumoricidal mitochondria
por: Kim, Hyueyun, et al.
Publicado: (2022)

Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?
por: Tarantelli, Chiara, et al.
Publicado: (2020)

Phenformin has anti-tumorigenic effects in human ovarian cancer cells and in an orthotopic mouse model of serous ovarian cancer
por: Jackson, Amanda L., et al.
Publicado: (2017)

Orlistat exerts anti-obesity and anti-tumorigenic effects in a transgenic mouse model of endometrial cancer
por: Xu, Guangxu, et al.
Publicado: (2023)

Genotype-Dependent Efficacy of a Dual PI3K/mTOR Inhibitor, NVP-BEZ235, and an mTOR Inhibitor, RAD001, in Endometrial Carcinomas
por: Shoji, Keiko, et al.
Publicado: (2012)

Efficacy of dual PI-3K and mTOR inhibitors in vitro and in vivo in acute lymphoblastic leukemia
por: Wong, Jacky, et al.
Publicado: (2014)

Structural insights of a PI3K/mTOR dual inhibitor with the morpholino-triazine scaffold
por: Takeda, Takako, et al.
Publicado: (2016)

A Novel Dual PI3K/mTOR Inhibitor, XIN-10, for the Treatment of Cancer
por: Luo, Leixuan, et al.
Publicado: (2023)

965. Applying Clinical Prediction Tools to Patients with Lassa Fever
por: Chiosi, John, et al.
Publicado: (2018)

VS-5584, a Novel PI3K-mTOR Dual Inhibitor, Inhibits Melanoma Cell Growth In Vitro and In Vivo
por: Shao, Zheren, et al.
Publicado: (2015)

All PI3Kinase signaling is not mTOR: dissecting mTOR-dependent and independent signaling pathways in T cells
por: Gamper, Christopher J., et al.
Publicado: (2012)

Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway
por: Chen, Dongshao, et al.
Publicado: (2018)

Inhibition of autophagy sensitizes malignant pleural mesothelioma cells to dual PI3K/mTOR inhibitors
por: Echeverry, N, et al.
Publicado: (2015)

Developing a novel dual PI3K–mTOR inhibitor from the prodrug of a metabolite
por: Zhou, Yan, et al.
Publicado: (2017)

Design, Synthesis and Biological Evaluation of Novel Phenylsulfonylurea Derivatives as PI3K/mTOR Dual Inhibitors
por: Zhao, Bingbing, et al.
Publicado: (2018)

The dual PI3K/mTOR inhibitor dactolisib elicits anti-tumor activity in vitro and in vivo
por: Shi, Fei, et al.
Publicado: (2017)

Co-Targeting PIM Kinase and PI3K/mTOR in NSCLC
por: Moore, Gillian, et al.
Publicado: (2021)

AKT phosphorylation as a predictive biomarker for PI3K/mTOR dual inhibition-induced proteolytic cleavage of mTOR companion proteins in small cell lung cancer
por: Hung, Ming-Chun, et al.
Publicado: (2022)

PI3K/AKT/mTOR Pathway in Angiogenesis
por: Karar, Jayashree, et al.
Publicado: (2011)

Targeting PI3K/mTOR Signaling in Cancer
por: Arcaro, Alexandre
Publicado: (2014)

965. Advanced Practice Providers in Infectious Disease: Educational Needs and Opportunities
por: Yoke, Leah H, et al.
Publicado: (2021)

Superior efficacy of co-treatment with the dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A against NSCLC
por: Piao, Junjie, et al.
Publicado: (2016)

Dual Pharmacological Targeting of the MAP Kinase and PI3K/mTOR Pathway in Preclinical Models of Colorectal Cancer
por: Pitts, Todd M., et al.
Publicado: (2014)

Correction: The dual PI3K/mTOR inhibitor dactolisib elicits anti-tumor activity in vitro and in vivo
por: Shi, Fei, et al.
Publicado: (2018)

BET protein inhibition evidently enhances sensitivity to PI3K/mTOR dual inhibition in intrahepatic cholangiocarcinoma
por: Miao, Xiaolong, et al.
Publicado: (2021)

Evaluation of a Dual PI3K/mTOR Inhibitor PF-04691502 against Bladder Cancer Cells
por: Shang, Xiaosong, et al.
Publicado: (2022)

Design, Synthesis, and Biological Evaluation of Sulfonamide Methoxypyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors
por: Gao, Haotian, et al.
Publicado: (2023)

Identification of phytochemical as a dual inhibitor of PI3K and mTOR: a structure-based computational approach
por: Kumar, B. Harish, et al.
Publicado: (2022)

PI3K/mTOR dual inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A synergistically exert anti-tumor activity in breast cancer
por: Chen, Liyan, et al.
Publicado: (2017)

Targeting PI3K/Akt/mTOR Signaling in Cancer
por: Porta, Camillo, et al.
Publicado: (2014)

Multipoint targeting of the PI3K/mTOR pathway in mesothelioma
por: Zhou, S, et al.
Publicado: (2014)

PI3K/Akt/mTOR inhibitors in breast cancer
por: Lee, Joycelyn JX, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_06rhmh9bok82usamqb9j6inu95